PRECIGEN, INC. Business Acquisition, Pro Forma Net Income (Loss)
PRECIGEN, INC. (PGEN) reported Business Acquisition, Pro Forma Net Income (Loss) of -$97.21 million for the 9-month period ending 2017-09-30, per its 10-Q filed 2018-11-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2018-11-08
- PRECIGEN, INC. business acquisition, pro forma net income (loss) for the quarter ending 2017-09-30 was -$39.69M.
- PRECIGEN, INC. business acquisition, pro forma net income (loss) for the quarter ending 2017-06-30 was -$22.50M.
- PRECIGEN, INC. business acquisition, pro forma net income (loss) for the quarter ending 2017-03-31 was -$35.25M.
- PRECIGEN, INC. business acquisition, pro forma net income (loss) for the quarter ending 2016-09-30 was -$30.51M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month |
|---|---|---|---|
| 2017-09-30 | -$39.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$62.19M derived: sum of 2 quarters · filed 2018-11-08 | -$97.21M 10-Q · filed 2018-11-08 |
| 2017-06-30 | -$22.50M 10-Q · filed 2018-08-13 | -$57.52M 10-Q · filed 2018-08-13 | |
| 2017-03-31 | -$35.25M 10-Q/A · filed 2018-08-13 | ||
| 2016-09-30 | -$30.51M 10-Q · filed 2017-11-09 | -$80.89M derived: sum of 2 quarters · filed 2017-11-09 | -$147.50M 10-Q · filed 2017-11-09 |
| 2016-06-30 | -$50.39M 10-Q · filed 2017-08-09 | -$117.00M 10-Q · filed 2017-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |